• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes.

作者信息

Fernández-Garibay Valeria Michelle, Chavez-Tapia Norberto C

机构信息

Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Toriello Guerra, 14050 Mexico City, Mexico.

Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Toriello Guerra, 14050 Mexico City, Mexico.

出版信息

Ann Hepatol. 2025 Jan-Jun;30(1):101778. doi: 10.1016/j.aohep.2025.101778. Epub 2025 Jan 17.

DOI:10.1016/j.aohep.2025.101778
PMID:39828056
Abstract
摘要

相似文献

1
The rationale for the aggressive progression of MASLD in patients with type 2 diabetes.2型糖尿病患者中MAFLD进展迅速的原因。
Ann Hepatol. 2025 Jan-Jun;30(1):101778. doi: 10.1016/j.aohep.2025.101778. Epub 2025 Jan 17.
2
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.2 型糖尿病患者中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球流行病学。
Clin Gastroenterol Hepatol. 2024 Oct;22(10):1999-2010.e8. doi: 10.1016/j.cgh.2024.03.006. Epub 2024 Mar 21.
3
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
4
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.非酒精性脂肪性肝病（MASLD）/非酒精性脂肪性肝炎（MASH）：是否有必要进行标记？全面的叙述性综述。
Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462.
5
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.代谢相关脂肪性肝病时代非侵入性评分和血清生物标志物在脂肪性肝病中的应用：从非酒精性脂肪性肝病到代谢相关脂肪性肝病和脂肪性肝病的综合评价。
Curr Obes Rep. 2024 Sep;13(3):510-531. doi: 10.1007/s13679-024-00574-z. Epub 2024 May 29.
6
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
7
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
8
Metabolic Muddle. MASLD and MASH on the Horizon.代谢混乱。MASLD 和 MASH 即将出现。
J Insur Med. 2023 Jul 1;50(2):147-149. doi: 10.17849/insm-50-2-147-149.1.
9
Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.代谢功能障碍相关脂肪性肝病与2型糖尿病：致命协同作用
touchREV Endocrinol. 2024 Oct;20(2):5-9. doi: 10.17925/EE.2024.20.2.2. Epub 2024 Apr 23.
10
DNA Methylation and Target Gene Expression in Fatty Liver Progression From Simple Steatosis to Advanced Fibrosis.从单纯性脂肪变性到肝纤维化进展过程中脂肪肝的DNA甲基化与靶基因表达
Liver Int. 2025 Mar;45(3):e70040. doi: 10.1111/liv.70040.

引用本文的文献

1
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.代谢功能障碍相关脂肪性肝病：分子机制、临床意义及新兴治疗策略
Int J Mol Sci. 2025 Mar 25;26(7):2959. doi: 10.3390/ijms26072959.
2
Impact of steatotic liver disease categories on atrial fibrillation in type 2 diabetes: a nationwide study.脂肪性肝病类别对2型糖尿病患者心房颤动的影响：一项全国性研究
Sci Rep. 2025 Apr 3;15(1):11430. doi: 10.1038/s41598-025-94783-8.